New Releases from NCBI BookshelfQuizartinib (Vanflyta): Indication: In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib maintenance monotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FMS-like tyrosine kinase 3 internal tandem duplication positive: Reimbursement Recommendation [Internet].​Quizartinib (Vanflyta): Indication: In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib maintenance monotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FMS-like tyrosine kinase 3 internal tandem duplication positive: Reimbursement Recommendation [Internet].

By /

Canada’s Drug Agency (CDA-AMC) recommends that Vanflyta should be reimbursed by public drug plans for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top